Primary Peritoneal Clear Cell Adenocarcinoma Clinical Trials in Buffalo, New York
2 recruitingBuffalo, New York
Showing 1–2 of 2 trials
Recruiting
Phase 2
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+12 more
Roswell Park Cancer Institute60 enrolled1 locationNCT04919629
Recruiting
Phase 2
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
Platinum-Sensitive Ovarian CarcinomaRecurrent Ovarian CarcinomaRecurrent Fallopian Tube Carcinoma+12 more
Roswell Park Cancer Institute80 enrolled2 locationsNCT05231122